Overview of Flaxseed Oil (ALA) vs. Fish Oil (EPA/DHA) Omega-3 in Multiple Sclerosis Management
The Overcoming MS Program favours flaxseed oil omega-3 (ALA) over fish oil omega-3 (EPA, DHA) for MS protection and management of symptoms. Multiple sclerosis (MS) is a chronic autoimmune condition affecting the central nervous system, where inflammation and demyelination lead to symptoms like fatigue, disability progression, and relapses. Omega-3 fatty acids, including alpha-linolenic acid (ALA) from plant sources like flaxseed oil and eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) from fish oil, have been studied for their potential anti-inflammatory and neuroprotective effects in MS. While both types show some associations with improved outcomes, evidence from large observational studies suggests plant-based ALA in flaxseed oil may offer stronger benefits in reducing relapse rates, improving quality of life (QoL), and lowering MS risk or progression compared to animal-based EPA/DHA. Below is a summary of key research, focusing on comparative findings.
Key Findings from the HOLISM Study
The Health Outcomes and Lifestyle Interventions in a Sample of People with Multiple Sclerosis (HOLISM) study, an international observational cohort of over 2,400 participants with MS, examined associations between lifestyle factors, including omega-3 intake, and health outcomes like QoL, disability, relapse rates, and disease activity. Frequent fish consumption (3+ times weekly) was linked to better QoL across all domains (mental, physical, pain, energy), reduced disability (68% higher odds of mild disability), and trends toward fewer relapses (51% reduction). General omega-3 supplementation showed similar patterns, with higher doses (11+ ml/day) correlating with stronger benefits. However, when comparing supplementation types, flaxseed oil (rich in ALA) outperformed fish oil (rich in EPA/DHA): flaxseed users had higher QoL scores, 42% better odds of mild disability, a 61% reduction in relapse rates over 12 months, and 61% lower odds of worsening disease activity. Combinations of both oils were intermediate, but flaxseed alone showed the most significant effects. The study recommended prioritizing flaxseed oil in future randomized controlled trials (RCTs) due to its superior associations.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3821380/
- https://overcomingms.org/program/diet/flaxseed-oil
Evidence from the Nurses’ Health Study Cohorts
In two large prospective cohorts (Nurses’ Health Study and Nurses’ Health Study II, involving over 175,000 women followed for up to 20 years), higher dietary intake of polyunsaturated fatty acids (PUFAs) was associated with lower MS risk (HR 0.67 for top vs. bottom quintile). Among specific PUFAs, only ALA intake showed a strong inverse relationship (HR 0.61 for top vs. bottom quintile), while EPA and DHA were not linked to reduced risk. This suggests plant-based omega-3s like those in flaxseed may play a protective role in MS onset, potentially through anti-inflammatory mechanisms, whereas fish-derived forms do not show the same preventive effect.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5494026/
- https://pubmed.ncbi.nlm.nih.gov/28156186/
A related Harvard-led analysis of blood ALA levels in people with clinically isolated syndrome (CIS, an early MS precursor) found that those with the highest ALA concentrations were about 60% less likely to progress to definite MS, further supporting ALA’s role in slowing disease advancement.
- https://www.healthcentral.com/news/multiple-sclerosis/plant-based-omega-3s-may-reduce-ms-risk
Conclusion
Observational evidence from HOLISM and the Nurses’ Health Studies consistently points to flaxseed oil (ALA) providing greater benefits than fish oil (EPA/DHA) in reducing MS relapses, improving QoL and disability, and lowering disease risk or progression. RCTs and meta-analyses show mixed results for omega-3s overall, with limited direct comparisons, suggesting the need for more targeted trials on ALA specifically. While both sources may support anti-inflammatory processes, plant-based options appear more strongly substantiated for MS management in current data. Lifestyle factors like overall diet quality and vitamin D intake also interact with these associations, emphasizing a holistic approach.